TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced significant changes to its corporate governance structure. The company proposes to abolish its Supervisory Committee, transferring its responsibilities to the Board’s audit committee, and plans to amend its articles of association and internal governance measures, pending shareholder approval. Additionally, the term of an independent non-executive director, Dr. Lu Chuan, is set to expire, and the company proposes the election of Mr. Pu Hong as his replacement. These changes aim to streamline governance and align with regulatory guidelines, potentially impacting the company’s operational efficiency and stakeholder relations.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceutical products, with a market presence primarily in China.
Average Trading Volume: 1,265,709
Technical Sentiment Signal: Buy
Current Market Cap: HK$16.96B
See more insights into 9989 stock on TipRanks’ Stock Analysis page.